Article
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase.
Leukemia research - 1 Feb 2012
Fathi Amir T, Arowojolu Omotayo, Swinnen Ian, Sato Takashi, Rajkhowa Trivikram, Small Donald, Marmsater Fredrik, Robinson John E, Gross Stefan David, Martinson Matthew, Allen Shelley, Kallan Nicholas C, Levis Mark
Abstract excerpt
Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) mutation have a poor prognosis, and FLT3 inhibitors are now under clinical investigation. PIM1, a serine/threonine kinase, is up-regulated in FLT3-ITD AML and may be involved in FLT3-mediated leukemogenesis. We employed a PIM1 inhibitor, AR00459339 (Array Biopharma Inc.), to investigate the effect of PIM1 inhibition in...
Topics
- Apoptosis
- Blotting, Western
- Bone Marrow
- Colony-Forming Units Assay
- Drug Therapy, Combination
- Humans
- Immunoprecipitation
- Leukemia, Myeloid, Acute
- Mutation
- Phosphorylation